SAB Biotherapeutics, Inc. (SABS)

Market Cap	39.58M
Revenue (ttm)	2.24M
Net Income (ttm)	-42.19M
Shares Out	9.23M
EPS (ttm)	-7.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	825
Open	4.310
Previous Close	4.410
Day's Range	4.290 - 4.310
52-Week Range	4.000 - 11.900
Beta	0.80
Analysts	Strong Buy
Price Target	15.50 (+261.31%)
Earnings Date	May 14, 2024

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: SABS

Financial Performance

In 2023, SABS's revenue was $2.24 million, a decrease of -90.63% compared to the previous year's $23.90 million. Losses were -$42.19 million, 125.1% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for SABS stock is "Strong Buy." The 12-month stock price forecast is $15.5, which is an increase of 261.31% from the latest price.

Price Target

$15.5

(261.31% upside)

Analyst Consensus: Strong Buy